-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Monkeypox stocks SIGA, GOVX, BVNRY, CHMX, EBS soar on global health emergency
Monkeypox stocks SIGA, GOVX, BVNRY, CHMX, EBS soar on global health emergency
The World Health Organization has declared monkeypox a public health emergency. Infections are rising rapidly, including in the U.S. The rapid spread of the virus has investors jumping on so-called monkeypox stocks. As with Covid-19, not all will be winners.
Monkeypox Solutions Are Built on Smallpox
The stocks that are jumping mainly offer anti-viral drugs or vaccines in use against smallpox.
$SIGA Technologies(SIGA.US)$ is up almost 23% thanks to TPOXX, an oral drug used to treat smallpox. The drug is not yet approved for monkeypox in the U.S., but has been approved in Europe. Its market capitalization early on July 25 was $1.1 billion.
$GeoVax Labs(GOVX.US)$ is a pre-revenue company with a market cap of just $13 million. The stock jumped by two-thirds overnight on hopes its Modified Vaccinia Ankara-Virus Like Particle (MVA) vaccine program can quickly yield a monkeypox vaccine.
Bavarian Nordic (OTCMKTS:BVNRY) said it won European approval to apply its IMVANEX vaccine, already used against smallpox, to monkeypox. It has a market cap of $3.4 billion on 2021 sales of about $1.9 billion.
$Chimerix(CMRX.US)$ makes Tembexa, a drug used to treat smallpox. The U.S. Food and Drug Administration (FDA) is pursuing an expanded protocol to test it against monkeypox. It has a market cap of $188 million but 2021 revenue of just under $2 million.
$Emergent BioSolutions(EBS.US)$ bought Tembexa from Chimerix in May, in an agreement that could include royalties. Emergent has a market cap of $1.66 billion on $1.8 billion of 2021 sales. Its product line already includes vaccines against anthrax and smallpox.
What Happens Now for Monkeypox Stocks?
The moves on all these companies are pure speculation, largely based on similarities between the smallpox virus and monkeypox. Whether vaccines and treatments for the former will work on the latter remains unclear.
How rapidly the story unfolds at the regulatory level will determine whether these companies go anywhere in the drug market, as opposed to the stock market. There could also be other companies in the mix, and the chances of a large drug company buying one of the monkeypox players can't be discounted.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
On the date of publication, Dana Blankenhorn held no positions in any companies mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The World Health Organization has declared monkeypox a public health emergency. Infections are rising rapidly, including in the U.S. The rapid spread of the virus has investors jumping on so-called monkeypox stocks. As with Covid-19, not all will be winners.
世界衛生組織已經宣布猴痘為公共衛生緊急情況。感染正在迅速上升,包括在美國,病毒的快速傳播使投資者在所謂的猴痘股上跳躍。與 Covid-19 一樣,並非所有人都會成為贏家。
Monkeypox Solutions Are Built on Smallpox
猴痘解決方案建立在天花
The stocks that are jumping mainly offer anti-viral drugs or vaccines in use against smallpox.
跳躍的股票主要提供抗病毒藥物或疫苗用於對抗天花。
$SIGA Technologies(SIGA.US)$ is up almost 23% thanks to TPOXX, an oral drug used to treat smallpox. The drug is not yet approved for monkeypox in the U.S., but has been approved in Europe. Its market capitalization early on July 25 was $1.1 billion.
$ 西加技術(美國)$ 由於 TPOXX 是一種用於治療天花的口服藥物,幾乎增加了 23%。這種藥物尚未批准用於猴痘在美國, 但已被批准在歐洲.它在 7 月 25 日初的市值為 11 億美元。
$GeoVax Labs(GOVX.US)$ is a pre-revenue company with a market cap of just $13 million. The stock jumped by two-thirds overnight on hopes its Modified Vaccinia Ankara-Virus Like Particle (MVA) vaccine program can quickly yield a monkeypox vaccine.
美元 Geovax 實驗室 (政府) $ 是一家收入前的公司,市值僅為 1,300 萬美元。該股票在一夜之間飆升了三分之二,希望其修改過的 Vaccinia 安卡拉病毒粒子(MVA)疫苗計劃可以快速產生猴痘疫苗。
Bavarian Nordic (OTCMKTS:BVNRY) said it won European approval to apply its IMVANEX vaccine, already used against smallpox, to monkeypox. It has a market cap of $3.4 billion on 2021 sales of about $1.9 billion.
巴伐利亞北歐 (支持:BVNRY)表示,它贏得了歐洲的批准,將已經用於對天花的 IMVANEX 疫苗應用於猴痘。它的 2021 年銷售額約為 34 億美元的市值約為 19 億美元。
$Chimerix(CMRX.US)$ makes Tembexa, a drug used to treat smallpox. The U.S. Food and Drug Administration (FDA) is pursuing an expanded protocol to test it against monkeypox. It has a market cap of $188 million but 2021 revenue of just under $2 million.
$ 嵌梅里克 (CMRX) $ 使得天花, 一種用於治療天花的藥物.美國食品和藥物管理局(FDA)正在尋求擴展的協議,以對猴痘進行 test。它的市值為 1.88 億美元,但 2021 年的收入剛好不到 2 萬美元。
$Emergent BioSolutions(EBS.US)$ bought Tembexa from Chimerix in May, in an agreement that could include royalties. Emergent has a market cap of $1.66 billion on $1.8 billion of 2021 sales. Its product line already includes vaccines against anthrax and smallpox.
$ 緊急生物解決方案(EBS 美元) 在一項可能包括特許權使用費的協議中,從 Chiamerix 購買了 Tembexa。緊急情報的市值為 1.66 億美元,達到 8 億美元的 2021 年銷售額。其產品線已經包括針對炭疽病和天花的疫苗。
What Happens Now for Monkeypox Stocks?
現在猴痘股票會發生什麼?
The moves on all these companies are pure speculation, largely based on similarities between the smallpox virus and monkeypox. Whether vaccines and treatments for the former will work on the latter remains unclear.
所有這些公司的舉動都是純粹的猜測,主要是基於天花病毒和猴痘之間的相似之處。前者的疫苗和治療方法是否適用於後者尚不清楚。
How rapidly the story unfolds at the regulatory level will determine whether these companies go anywhere in the drug market, as opposed to the stock market. There could also be other companies in the mix, and the chances of a large drug company buying one of the monkeypox players can't be discounted.
故事如何迅速展開在監管層面將決定這些公司是否去任何地方在藥物市場, 而不是股市.也可能有其他公司在混合, 和大型藥品公司購買猴痘球員之一的機會不能打折.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
在細價股票和低交易量股票上:只有最稀有的例外情況,InvestorPlace 不會發布有關市值低於 1 億美元或每天交易少於 100,000 股的公司的評論。這是因為這些「細價股」通常是騙局藝術家和市場操縱者的遊樂場。如果我們確實發布了可能受到評論影響的低交易量股票的評論,我們要求投資者關係網的作家披露了這一事實,並警告讀者風險。
On the date of publication, Dana Blankenhorn held no positions in any companies mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,達納·布蘭肯霍恩在本文中提到的任何公司都不擔任任何職位。本文中表達的意見是作者的意見,受到投資者的影響。 出版指南。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧